OncoMark tests are designed to be supplied in kit format and performed using standard PCR equipment thereby enabling users to perform the test in their own laboratories where and when required. Our lead product, the OncoMasTR test, will be CE Marked under the IVD Directive and launched in Europe in 2018. In parallel, we are pursuing a regulatory and commercial roadmap targeting a launch in other territories in late 2018 / 2019.
Therefore, we are actively seeking to partner with a select number of distribution and clinical laboratory partners to make this high value test available to a global customer base.
If you wish to learn more about partnering with us on the commercialisation of the OncoMasTR test, please contact us directly.